Skip to main content

Advertisement

Log in

Clinical pharmacokinetics of melatonin: a systematic review

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the review was to provide an overview of studies investigating the pharmacokinetics of exogenous melatonin in humans and if possible, to provide recommendations for clinical use.

Methods

The review was conducted in accordance to PRISMA guidelines. A systematic literature search was performed in PubMed and Embase databases. The pharmacokinetic variables included maximal plasma/serum concentration (Cmax), time to maximal plasma/serum concentration (Tmax), elimination half-life (T1/2), area-under-the-curve plasma/serum concentrations (AUC), clearance (Cl), volume of distribution (VD), and bioavailability.

Results

The literature search identified 392 records. Twenty-two studies were included in the review. Melatonin dosages varied between 0.3 and 100 mg and were administered either orally or intravenously. Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral). Tmax ranged between 15 (2 mg) and 210 min (10 mg). T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 1010 pg/ml × min (1 mg, oral). Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral). Bioavailability of oral melatonin ranged from 9 to 33 %. Pharmacokinetics was affected by age, caffeine, smoking, oral contraceptives, feeding status, and fluvoxamine. Critically ill patients displayed accelerated absorption and compromised elimination.

Conclusions

Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin. T1/2 was 45 min in both administration routes. Cmax, AUC, Cl, and VD varied extensively between studies. Bioavailability of oral melatonin was approximately 15 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Brzezinski A (1997) Melatonin in humans. N Engl J Med 336:186–195

    Article  CAS  PubMed  Google Scholar 

  2. Andersen LPH, Werner MU, Rosenberg J, Gögenur I (2014) A systematic review of peri-operative melatonin. Anaesthesia 69:1163–1171

    Article  CAS  PubMed  Google Scholar 

  3. Bourne RS, Mills GH, Minelli C (2008) Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomized controlled trail. Crit Care 12:R52

    Article  PubMed Central  PubMed  Google Scholar 

  4. Borazan H, Tuncer S, Yalcin N, Erol A, Otelcioglu S (2010) Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial. J Anesth 24:155–160

    Article  PubMed  Google Scholar 

  5. Caumo W, Torres F, Moreia NL, Auzani JAS, Monteiro CA, Londero G, Ribeiro DFM, Hidalgo MPL (2007) The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 105:1263–1271

    Article  CAS  PubMed  Google Scholar 

  6. Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B (2004) Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 39:184–189

    Article  CAS  PubMed  Google Scholar 

  7. Kücükakin B, Lykkesfeldt J, Nielsen HJ, Reiter RJ, Rosenberg J, Gögenur I (2008) Utility of melatonin to treat surgical stress after major vascular surgery—a safety study. J Pineal Res 44:426–431

    Article  PubMed  Google Scholar 

  8. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40:781–784

    Article  CAS  PubMed  Google Scholar 

  9. Di WL, Kadva A, Johnston A, Silman R (1997) Variable bioavailability of oral melatonin. N Engl J Med 336:1028–1029

    Article  CAS  PubMed  Google Scholar 

  10. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341

    Article  PubMed  Google Scholar 

  11. Zhdanova IV, Wurtman RJ, Balcioglu A, Kartashov AI, Lynch HJ (1998) Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J Gerontol 53:B293–B298

    Article  CAS  Google Scholar 

  12. Cavallo A, Ritschel WA (1996) Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab 81:1882–1886

    CAS  PubMed  Google Scholar 

  13. Vakkuri O, Leppäluoto J, Kauppila A (1985) Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci 37:489–495

    Article  CAS  PubMed  Google Scholar 

  14. Shirakawa SI, Tsuchiya S, Tsutsumi Y, Kotorii T, Uchimura N, Sakamoto T, Yamada S (1998) Time course of saliva and serum melatonin levels after ingestion of melatonin. Psychiatry Clin Neurosci 52:266–267

    Article  CAS  PubMed  Google Scholar 

  15. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ (1984) Bioavailability of oral melatonin in humans. Neuroendocrinology 39:307–311

    Article  CAS  PubMed  Google Scholar 

  16. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E, Esposti R, DeMartini G, Fraschini F, Rezzani R, Reiter RJ, Iapichino G (2010) Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 48:142–147

    Article  CAS  PubMed  Google Scholar 

  17. Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K (2003) Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol 56:679–682

    Article  PubMed Central  PubMed  Google Scholar 

  18. Mallo C, Zaîdan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B (1990) Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 38:297–301

    Article  CAS  PubMed  Google Scholar 

  19. Ursing C, Bhar CV, Brismar K, Röjdmark S (2005) Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol 61:197–201

    Article  CAS  PubMed  Google Scholar 

  20. Fourtillan JB, Brisson AM, Gobin P, Ingrand I, Decourt JPH, Girault J (2000) Bioavailability of melatonin in humans after day-time administration of D7 Melatonin. Biopharm Drug Dispos 21:15–22

    Article  CAS  PubMed  Google Scholar 

  21. Gooneratne NS, Edwards AYZ, Zhou C, Cuellar N, Grandner MA, Barrett JS (2012) Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res 52:437–445

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Markantonis SL, Tsakalozou E, Paraskeva A, Staikou C, Fassoulaki A (2008) Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol 48:240–245

    Article  CAS  PubMed  Google Scholar 

  23. Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, Laine K (2008) The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C > A polymorphism. J Clin Pharmacol 48:986–994

    Article  CAS  PubMed  Google Scholar 

  24. Le Bars D, Thivolle P, Vitte PA, Bojkowski C, Chazot G, Arendt J, Frackowiak RSJ, Claustrat B (1991) PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humans. Nucl Med Biol 18:357–362

    Google Scholar 

  25. Aldhous M, Franey C, Wright J, Arendt J (1985) Plasma concentrations of melatonin in man following oral absorption of different preparations. J Clin Pharmacol 19:517–521

    Article  CAS  Google Scholar 

  26. López-Gamboa M, Canales-Gómez JS, Castro Sandoval TJ, Tovar EN, Mejía MA, Baltazar MAM, Palma-Aguirre JA (2010) Bioavailability of long acting capsules of melatonin in Mexican healthy volunteers. J Bioequiv Availab 2:116–119

    Article  Google Scholar 

  27. Proietti S, Carlomagno G, Dinicola S, Bizzarri M (2014) Soft gel capsules improve melatonin’s bioavailability in humans. Expert Opin Drug Metab Toxicol 10:1193–1198

    Article  CAS  PubMed  Google Scholar 

  28. Hoffmann H, Dittgen M, Hoffmann A, Bartsch C, Breitbarth H, Timpe C, Farker K, Schmidt U, Mellinger U, Zimmermann H, Gräser T, Oettel M (1998) Evaluation of an oral pulsatile delivery system for melatonin in humans. Pharmazie 53:462–466

    CAS  PubMed  Google Scholar 

  29. Härrter S, Grözinger M, Wiegmann H, Röschke J, Hiemke C (2000) Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 67:1–6

    Article  Google Scholar 

  30. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007) One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42:28–42

    Article  CAS  PubMed  Google Scholar 

  31. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://www.cochrane-handbook.org. Accessed 16 Dec 2014

  32. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds JM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trails: is blinding necessary? Contemp Clin Trails 17:1–12

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nathja Groth Harpsøe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harpsøe, N.G., Andersen, L.P.H., Gögenur, I. et al. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol 71, 901–909 (2015). https://doi.org/10.1007/s00228-015-1873-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1873-4

Keywords

Navigation